Drugs / 4SCAR19 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02968472 | Mar 2015 → May 2019 | B-cell acute lymphoblastic leukemia | The First People's Hospital of Yunnan | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SCAR19 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02968472 ↗ |
| Modality | Cell therapy | “A chimeric antigen receptor gene-modified T cells (CART: 4SCAR19)” NCT02968472 ↗ |
| Target | CD19 | “targeted the CD19 (cluster of differentiation antigen 19)” NCT02968472 ↗ |